Article

FDA Approves Inrebic to Treat Myelofibrosis

Author(s):

The Food and Drug Administration approved Inrebic as the first new treatment in nearly a decade for patients with myelofibrosis.

The Food and Drug Administration (FDA) approved Inrebic (fedratinib) as the first new treatment in nearly a decade for patients with myelofibrosis, according to Celgene — the agent’s manufacturer.

“Myelofibrosis can cause patients to suffer in many ways, including experiencing debilitating symptoms,” Dr. Ruben Mesa, director of the Mays Cancer Center at UT Health San Antonio Cancer Center MD Anderson, said in a press release. “There has not been a new treatment approved for this disease in nearly a decade. With Inrebic, physicians and patients now have another option available for myelofibrosis.”

Myelofibrosis is a serious and rare bone marrow disorder that disrupts the body’s normal production of blood cells, which can lead to anemia, weakness, fatigue and enlargement of the spleen and liver, among other symptoms.

The agency approved the JAK-2 inhibitor for treatment in patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis based on findings from the JAKARTA trial.

The study demonstrated that patients experienced a 35% or great spleen volume reduction. Serious side effects included cardiac failure (5%) and anemia (2%).

Check back later for more information on what this approval means for patients.

Related Videos
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Related Content